| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1923 | Eidd-1619 | Novel water-soluble analog of progesterone |
|
| DCC1924 | Eidd-1723 | Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity |
|
| DCC1925 | Eif4a Inhibitor 28 | Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr |
|
| DCC1926 | Ejmch-6 | Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus |
|
| DCC1927 | Ejr-866-75 | Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
| DCC1928 | Ejr-866-81 | Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
| DCC1929 | El-0052 | Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable |
|
| DCC1930 | El-228 | Novel inhibitor of Aurora B kinase |
|
| DCC1931 | Ela23-32 | Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA |
|
| DCC1932 | elaidyl-sulfamide | Oleoylethanolamide-modelled PPAR |
|
| DCC1933 | Elnd006 | Novel γ-secretase inhibitor |
|
| DCC1934 | Elovl1 Inhibitor 22 | Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme |
|
| DCC1935 | Elx-02 | Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein |
|
| DCC1936 | Em20-25 | Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine |
|
| DCC1937 | em-800 | High affinity ligand for estrogen receptor- |
|
| DCC1938 | Emac4001 | Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines |
|
| DCC1939 | Emd-1204831 | Novel potent and highly selective c-Met inhibitor |
|
| DCC1940 | Emd57439 | PDE 3 inhibitor |
|
| DCC1941 | Emd-66684 | Non-peptide angiotensin II receptor antagonist |
|
| DCC1942 | Emdb-1 | Novel peptide endomorphin (EM) degradation blocker |
|
| DCC1943 | Emdb-2 | Novel peptide endomorphin (EM) degradation blocker |
|
| DCC1944 | Emdb-3 | Novel peptide endomorphin (EM) degradation blocker |
|
| DCC1945 | Emicerfont | Novel corticotropin-release factor 1 antagonist |
|
| DCC1946 | Emitefur | 5-FU derivative, with various anticancer agents against human cancer xenografts |
|
| DCC1947 | Eml108 | Novel PRMT inhibitor, preventing arginine methylation of cellular proteins, being essentially inactive against the lysine methyltransferase SET7/9 |
|
| DCC1948 | Eml981 | Novel Potent and Selective Inhibitor of Protein Arginine Methyltransferase 4 (PRMT4) |
|
| DCC1949 | Emoxypine Succinate | Antioxidant, inhibiting free radical oxidation of biomembrane lipids, modulating the activity of membrane-bound enzymes and the receptor complexes of the brain membranes |
|
| DCC1950 | En3356 | Novel non-steroidal CYP17 inhibitor. reducing androgen synthesis for treatment of castration-resistant prostate cancer |
|
| DCC1951 | Ena739155 | Novel butyrylcholinesterase inhibitor against Alzheimer's disease |
|
| DCC1952 | Encenicline | Novel Potentiator of α7 Receptor Signaling |
|
